Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon

Executive Summary

Neuropharm R&D firm signs R&D and licensing agreement with Boston University for rights to key enzymes that may be partially responsible for development of amyloid plaques in Alzheimer's patients, West Chester, Pa.-based Cephalon announces. BU and the firm will work to identify the proteins and then design inhibitors to stop the development of amyloid plaques. New agreement should complement the $ 20 mil., five-year R&D agreement with Schering- Plough signed in June 1990 for development of brain protease inhibitors as Alzheimer's therapeutics. Cephalon said May 29 that it had received the second $ 5 mil. payment from the Schering agreement.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel